Application deadline 17 August 2022
Start feeling the excitement and check the programme for the latest updates
Take part in the leading global meeting dedicated to understanding molecular developments that can help in making cancer treatment more personalised
From the World Conference on Lung Cancer 2022:
Interim overall survival results show a trend in favour of adjuvant atezolizumab for NSCLC patients with stage II–IIIA, PD-L1-positive disease
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.